NCCN
Lynparza Benefit in Early BRCA-Mutated Breast Cancer Reignites Universal Genetic Testing Discussion
Premium
The OlympiA trial showed a disease-free survival benefit with adjuvant PARP inhibitor therapy for early-stage, BRCA1/2-mutated, HER2-negative breast cancer patients.
NCCN Publishes First Set of Guidelines for Wilms Tumor
In addition to treatment regimens, the guidelines include recommendations for molecular testing and surveillance for patients with predisposition syndromes.
Biotheranostics' Breast Cancer Index Included in Latest NCCN Guidelines
The expert body now recognizes the test's ability to predict whether early-stage breast cancer patients will benefit from extended, adjuvant endocrine therapy.
Genetic Testing Challenges in Oncology: BRCA2-Positive Healthy Young Man Recommended Mastectomy
A case series in partnership with My Gene Counsel to highlight the challenges genetics professionals and oncologists are grappling with as genetic testing is increasingly used in patient care.
Genetic Testing Challenges in Oncology: Surgeon Recommends Mastectomy for Woman With RAD50 Mutation
A case series in partnership with My Gene Counsel to highlight the challenges genetics professionals and oncologists are grappling with as genetic testing is increasingly used in patient care.